uploads/2017/12/Analysts-Ratings-4-1.png

Analyst Recommendations for Alexion in December 2017

By

Updated

Recent collaboration

In December 2017, Alexion Pharmaceuticals (ALXN) and Halozyme Therapeutics entered into a license agreement that allows Alexion to use Halozyme’s Enhanze drug delivery technology for the development of subcutaneous formulations for Alexion’s product portfolio.

The license agreement grants Alexion the opportunity to exclusively develop up to four targets, including Alexion’s next-generation subcutaneous formulation of ALXN1210.

According to the agreement, Halozyme Therapeutics will receive an upfront payment of $40 million along with potential additional payments up to $160 million for each target developed, subject to the accomplishment of specified development, regulatory approvals, and other market sales-based indicators. The license agreement is expected to strengthen Alexion’s innovation potential.

Analyst ratings

Twenty-one analysts are tracking Alexion Pharmaceuticals in December 2017. Six of them are recommending a “strong buy,” while 12 are recommending a “buy.” Three analysts are recommending a “hold,” and none of them are recommending any form of a “sell.”

On December 7, 2017, Alexion Pharmaceuticals had a consensus 12-month target price of $163.43, which represents a ~53.1% return on investment over the next 12 months. The Vanguard S&P 500 ETF (VOO) invests 0.13% of its total portfolio holdings in Alexion Pharmaceuticals.

Competitor ratings

Of the 26 analysts tracking Vertex Pharmaceuticals (VRTX) in December 2017, 81% of them have recommended some form of a “buy.” On December 7, 2017, Vertex Pharmaceuticals had a consensus 12-month target price of $182.91, which represents a 31.8% return on investment over the next 12 months.

Of the 24 analysts tracking BioMarin Pharmaceutical (BMRN) in December 2017, 79% of them are recommending some form of a “buy.” On December 7, 2017, BioMarin Pharmaceutical had a consensus 12-month target price of $114, which represents a 40.9% return on investment over the next 12 months.

Of the 33 analysts tracking Biogen Idec (BIIB) in December 2017, 64% of them are recommending some form of a “buy.” On December 7, 2017, Biogen had a consensus 12-month target price of $358.42, which represents a ~12.2% return on investment over the next 12 months.

More From Market Realist